BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37586782)

  • 1. The status and challenges of HPV vaccine programme in China: an exploration of the related policy obstacles.
    Wang H; Jiang Y; Wang Q; Lai Y; Holloway A
    BMJ Glob Health; 2023 Aug; 8(8):. PubMed ID: 37586782
    [No Abstract]   [Full Text] [Related]  

  • 2. Current issues facing the introduction of human papillomavirus vaccine in China and future prospects.
    Wong LP; Han L; Li H; Zhao J; Zhao Q; Zimet GD
    Hum Vaccin Immunother; 2019; 15(7-8):1533-1540. PubMed ID: 31017500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jabs for the boys: the case for gender-neutral HPV vaccination.
    Baker P
    Perspect Public Health; 2016 Jan; 136(1):28-9. PubMed ID: 26702116
    [No Abstract]   [Full Text] [Related]  

  • 4. The feasibility of universal HPV vaccination program in Shenzhen of China: a health policy analysis.
    Chen R; Wong E
    BMC Public Health; 2019 Jun; 19(1):781. PubMed ID: 31221112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the implementation of human papillomavirus and hepatitis B vaccination programs in the United States: Implications for future vaccines.
    Constable C; Caplan A
    Vaccine; 2020 Jan; 38(5):954-962. PubMed ID: 31843271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and acceptability of delivering adolescent health interventions alongside HPV vaccination in Tanzania.
    Watson-Jones D; Lees S; Mwanga J; Neke N; Changalucha J; Broutet N; Maduhu I; Kapiga S; Chandra-Mouli V; Bloem P; Ross DA
    Health Policy Plan; 2016 Jul; 31(6):691-9. PubMed ID: 26768827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives.
    Abdullahi LH; Hussey GD; Wiysonge CS; Kagina BM
    S Afr Med J; 2020 May; 110(6):525-531. PubMed ID: 32880566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
    Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
    Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus vaccine introduction--the first five years.
    Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
    Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early lessons learned from extramural school programs that offer HPV vaccine.
    Hayes KA; Entzel P; Berger W; Caskey RN; Shlay JC; Stubbs BW; Smith JS; Brewer NT
    J Sch Health; 2013 Feb; 83(2):119-26. PubMed ID: 23331272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early policy responses to the human papillomavirus vaccine in the United States, 2006-2010.
    Laugesen MJ; Mistry R; Carameli KA; Ribisl KM; Needleman J; Bastani R
    J Adolesc Health; 2014 Nov; 55(5):659-64. PubMed ID: 24928803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.
    Dorleans F; Giambi C; Dematte L; Cotter S; Stefanoff P; Mereckiene J; O'Flanagan D; Lopalco PL; D'Ancona F; Levy-Bruhl D;
    Euro Surveill; 2010 Nov; 15(47):. PubMed ID: 21144444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Another look at the human papillomavirus vaccine experience in Canada.
    Mah CL; Deber RB; Guttmann A; McGeer A; Krahn M
    Am J Public Health; 2011 Oct; 101(10):1850-7. PubMed ID: 21852642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?
    Osazuwa-Peters N
    Vaccine; 2013 Nov; 31(47):5500-5. PubMed ID: 24095883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Physician Recommendations and Public Policy in Human Papillomavirus Vaccinations.
    Moghtaderi A; Adams S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):349-59. PubMed ID: 26873090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Expanded Impact of Human Papillomavirus Vaccine.
    Pahud BA; Ault KA
    Infect Dis Clin North Am; 2015 Dec; 29(4):715-24. PubMed ID: 26610422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects.
    Wigle J; Coast E; Watson-Jones D
    Vaccine; 2013 Aug; 31(37):3811-7. PubMed ID: 23777956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenging 'girls only' publicly funded human papillomavirus vaccination programmes.
    Law VG; Gustafson DL
    Nurs Inq; 2017 Jan; 24(1):. PubMed ID: 27198909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in HPV vaccination in low- and lower-middle-income countries.
    LaMontagne DS; Bloem PJN; Brotherton JML; Gallagher KE; Badiane O; Ndiaye C
    Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():7-14. PubMed ID: 28691329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Australia leads way on HPV vaccination in boys.
    Wilkinson E
    Lancet Infect Dis; 2012 Nov; 12(11):831-2. PubMed ID: 23256210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.